Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Wesley H. Self,Mark W Tenforde,Jillian P. Rhoads,Manjusha Gaglani,Manjusha Gaglani,Adit A. Ginde,David J. Douin,Samantha M. Olson,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Tresa McNeal,Tresa McNeal,Shekhar Ghamande,Shekhar Ghamande,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber Shehu,Matthew E. Prekker,Heidi L Erickson,Michelle N. Gong,Amira Mohamed,Daniel J. Henning,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,Catherine L. Hough,Laurence W. Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Qadir,Steven Y. Chang,Christopher Mallow,Carolina Rivas,Hilary M. Babcock,Jennie H. Kwon,Matthew C. Exline,Natasha B. Halasa,James D. Chappell,Adam S. Lauring,Carlos G. Grijalva,Todd W. Rice,Ian Jones,William B. Stubblefield,Adrienne Baughman,Kelsey N Womack,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,Lisa Mills,Sandra N. Lester,Megan M. Stump,Eric A. Naioti,Miwako Kobayashi,Jennifer R. Verani,Natalie J. Thornburg,Manish M. Patel +63 more
Reads0
Chats0
TLDR
In this paper, a case-control analysis was conducted among 3,689 adults aged ≥18 years who were hospitalized at 21 U.S. hospitals across 18 states during March 11-August 15, 2021.Abstract:
Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged ≥18 years and aged ≥16 years, respectively. A 1-dose viral vector vaccine (Ad26.COV2 from Janssen [Johnson & Johnson]) received EUA in February 2021 for persons aged ≥18 years (3). The Pfizer-BioNTech vaccine received FDA approval for persons aged ≥16 years on August 23, 2021 (4). Current guidelines from FDA and CDC recommend vaccination of eligible persons with one of these three products, without preference for any specific vaccine (4,5). To assess vaccine effectiveness (VE) of these three products in preventing COVID-19 hospitalization, CDC and collaborators conducted a case-control analysis among 3,689 adults aged ≥18 years who were hospitalized at 21 U.S. hospitals across 18 states during March 11-August 15, 2021. An additional analysis compared serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2, the virus that causes COVID-19, among 100 healthy volunteers enrolled at three hospitals 2-6 weeks after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine. Patients with immunocompromising conditions were excluded. VE against COVID-19 hospitalizations was higher for the Moderna vaccine (93%; 95% confidence interval [CI] = 91%-95%) than for the Pfizer-BioNTech vaccine (88%; 95% CI = 85%-91%) (p = 0.011); VE for both mRNA vaccines was higher than that for the Janssen vaccine (71%; 95% CI = 56%-81%) (all p<0.001). Protection for the Pfizer-BioNTech vaccine declined 4 months after vaccination. Postvaccination anti-spike IgG and anti-RBD IgG levels were significantly lower in persons vaccinated with the Janssen vaccine than the Moderna or Pfizer-BioNTech vaccines. Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.read more
Citations
More filters
Journal ArticleDOI
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
TL;DR: A systematic review of the evidence for the duration of protection of COVID-19 vaccines against various clinical outcomes, and to assess changes in the rates of breakthrough infection caused by the delta variant with increasing time since vaccination was conducted as discussed by the authors .
Journal ArticleDOI
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review.
TL;DR: In this article, the authors provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for nineteen COVID-19 vaccines.
Journal ArticleDOI
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
TL;DR: In this paper , the authors provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for 19 COVID-19 vaccines.
Journal ArticleDOI
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Adam S. Lauring,Mark W Tenforde,James D. Chappell,Manjusha Gaglani,Adit A. Ginde,Tresa McNeal,Shekhar Ghamande,David J. Douin,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber N. Shehu,Matthew E. Prekker,Heidi L Erickson,Matthew C. Exline,Michelle N. Gong,Amira H. Mohamed,Nicholas J. Johnson,Vasisht Srinivasan,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,Catherine L. Hough,Laurence W. Busse,C. T. ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Abdul Qadir,Steven Y. Chang,Christopher Mallow,Carolina Gutiérrez Rivas,Hilary M. Babcock,Jennie H. Kwon,Natasha B. Halasa,Carlos G. Grijalva,Todd W. Rice,William B. Stubblefield,Adrienne Baughman,Kelsey N Womack,Jillian P. Rhoads,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,K. Adams,Stephanie J. Schrag,Samantha M. Olson,M. Kobayashi,Jennifer R. Verani,Manish M. Patel,Wesley H. Self +58 more
TL;DR:
Journal ArticleDOI
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.
Mark W Tenforde,Wesley H. Self,Katherine Adams,Manjusha Gaglani,Adit A. Ginde,Tresa McNeal,Shekhar Ghamande,David J. Douin,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber Shehu,Matthew E. Prekker,Heidi L Erickson,Matthew C. Exline,Michelle N. Gong,Amira Mohamed,Daniel J. Henning,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,Catherine L. Hough,Laurence W. Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Qadir,Steven Y. Chang,Christopher Mallow,Carolina Rivas,Hilary M. Babcock,Jennie H. Kwon,Natasha B. Halasa,James D. Chappell,Adam S. Lauring,Carlos G. Grijalva,Todd W. Rice,Ian Jones,William B Stubblefield,Adrienne Baughman,Kelsey N Womack,Jillian P. Rhoads,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,Samantha M. Olson,Miwako Kobayashi,Jennifer R. Verani,Manish M. Patel,Influenza +58 more
TL;DR: In this article, the authors evaluated the association between vaccination with mRNA COVID-19 vaccines and hospitalization, and the association with progression to critical disease, using multivariable logistic regression.
References
More filters
Journal ArticleDOI
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Journal ArticleDOI
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Srinivas Nanduri,Tamara Pilishvili,Gordana Derado,Minn M. Soe,Philip Dollard,Hsiu Wu,Qunna Li,Suparna Bagchi,Heather Dubendris,Ruth Link-Gelles,John A. Jernigan,Daniel S. Budnitz,Jeneita M. Bell,Andrea L. Benin,Nong Shang,Jonathan R. Edwards,Jennifer R. Verani,Stephanie J. Schrag +17 more
TL;DR: In this article, the authors evaluated the effectiveness of the two currently authorized mRNA COVID-19 vaccines against SARS-CoV-2 B.1.2 (Delta) and B.2.
Journal ArticleDOI
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.
Mark W Tenforde,Wesley H. Self,Eric A. Naioti,Adit A. Ginde,David J. Douin,Samantha M. Olson,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Manjusha Gaglani,Manjusha Gaglani,Tresa McNeal,Shekhar Ghamande,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber Shehu,Matthew E. Prekker,Heidi L Erickson,Michelle N. Gong,Amira Mohamed,Daniel J. Henning,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,Catherine L. Hough,Laurence W. Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Qadir,Steven Y. Chang,Christopher Mallow,Carolina Rivas,Hilary M. Babcock,Jennie H. Kwon,Matthew C. Exline,Natasha B. Halasa,James D. Chappell,Adam S. Lauring,Carlos G. Grijalva,Todd W. Rice,Ian Jones,William B. Stubblefield,Adrienne Baughman,Kelsey N Womack,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,Meagan Stephenson,Stephanie J. Schrag,Miwako Kobayashi,Jennifer R. Verani,Manish M. Patel +59 more
TL;DR: In this article, Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines were evaluated in 21 hospitals in 18 states and the duration of mRNA vaccine effectiveness against COVID19-associated hospitalizations was assessed among adults aged ≥18 years.
Journal ArticleDOI
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.
Mark W Tenforde,Manish M. Patel,Adit A. Ginde,David J. Douin,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Manjusha Gaglani,Tresa McNeal,Shekhar Ghamande,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber Shehu,Matthew E. Prekker,Heidi L Erickson,Matthew C. Exline,Michelle N. Gong,Amira Mohamed,Daniel J. Henning,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,C Terri Hough,Laurence W. Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Qadir,Steven Y. Chang,Christopher Mallow,Hayley B. Gershengorn,Hilary M. Babcock,Jennie H. Kwon,Natasha B. Halasa,James D. Chappell,Adam S. Lauring,Carlos G. Grijalva,Todd W. Rice,Ian Jones,William B Stubblefield,Adrienne Baughman,Kelsey N Womack,Christopher J. Lindsell,Kimberly W. Hart +49 more
TL;DR: In a multicenter case-control analysis of US adults hospitalized March 11-May 5, 2021, the authors evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid19 and hospital-based controls who tested negative for SARS-CoV-2.
Posted ContentDOI
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States
Mark W Tenforde,Manish M. Patel,Adit A. Ginde,David J. Douin,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Manjusha Gaglani,Tresa McNeal,Shekhar Ghamande,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber Shehu,Matthew E. Prekker,Heidi L Erickson,Matthew C. Exline,Michelle N. Gong,Amira Mohamed,Daniel J. Henning,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,C Terri Hough,Laurence W. Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Qadir,Steven Y. Chang,Christopher Mallow,Hayley B. Gershengorn,Hilary M. Babcock,Jennie H. Kwon,Natasha B. Halasa,James D. Chappell,Adam S. Lauring,Carlos G. Grijalva,Todd W. Rice,Ian Jones,William B Stubblefield,Adrienne Baughman,Kelsey N Womack,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,Samantha M. Olson,Meagan Stephenson,Stephanie J. Schrag,Miwako Kobayashi,Jennifer R. Verani,Wesley H. Self,Influenza +58 more
TL;DR: In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, the authors evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid19 and hospital-based controls who tested negative for SARS-CoV-2.
Related Papers (5)
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald C. Sadoff,Glenda Gray,An Vandebosch,Vicky Cardenas,Georgi Shukarev,Beatriz Grinsztejn,Paul A. Goepfert,Carla Truyers,Hein Fennema,Bart Spiessens,Kim Offergeld,Gert Scheper,Kimberly L Taylor,Merlin L. Robb,John J. Treanor,Dan H. Barouch,Jeffrey J. Stoddard,Martin Ryser,Mary A. Marovich,Kathleen M. Neuzil,Lawrence Corey,Nancy Cauwenberghs,Tamzin Tanner,Karin Hardt,Javier Ruiz-Guiñazú,Mathieu Le Gars,Hanneke Schuitemaker,Johan Van Hoof,Frank Struyf,Macaya Douoguih +29 more